Coverage / GILD / Trade Card

GILD

Gilead Sciences, Inc

BUY 2026-08-01 Updated today USD 130.21 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY
68

Position levels

Currenttoday
USD 130.21
Buy <=wait / entry
USD 116.67
Trim >=take some off
USD 140.00
Thesis breakA material deceleration in HIV franchise revenue, a negative Phase 3 readout fro...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case37%100 / 10037.0
Base case47%62 / 10029.1
Bear case16%10 / 1001.6
Weighted conviction68 / 100 - BUY

Top risks

  • Positive Phase 3 clinical trials for once-weekly long-acting HIV treatment
  • Key European regulatory approvals for Trodelvy
  • Analyst consensus Buy rating with average price target of $157.15
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.